Systemic Juvenile Idiopathic Arthritis Clinical Trials

23 clinical trials for Systemic Juvenile Idiopathic Arthritis across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients — RECRUITING
• Ilaris NIS in Korea — RECRUITING
• Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT — RECRUITING · PHASE2
• A study to assess the pharmacokinetics and safety of tocilizumab in patients with Active Systemic Juvenile Idiopathic Arthritis. — OTHER · PHASE1
• A Multi-Center, Open label, Repeated Dose Range Finding Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Efficacy of an Anti-IL-1β Monoclonal Antibody (ACZ885) Given Subcutaneously in Pediatric Subjects with Active Systemic Juvenile Idiopathic Arthritis (SJIA) — COMPLETED · PHASE2
• A study of a new sub-cutaneous formulation of Actemra/RoActemra in children with systemic juvenile idiopathic arthritis — COMPLETED · PHASE1
• A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA) — ACTIVE_NOT_RECRUITING · PHASE3
• An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase. Name: SKYPS — TERMINATED · PHASE2
• An Efficacy and Safety Study of Subcutaneous Anakinra in Chinese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD) — WITHDRAWN · PHASE4
• I4V-MC-JAHU: Open-Label, Randomized Study with a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children from 1 to Less Than 18 Years of Age with Systemic Juvenile Idiopathic Arthritis — OTHER · PHASE3
• Role of Interleukin 18 (IL-18) and Interleukin 18 Binding Protein (IL-18BP) in the Diagnostic Work-up of Systemic Juvenile Idiopathic Arthritis and Autoinflammatory Diseases: Possible Biomarkers in the Differential Diagnosis of Other Febrile Diseases — NOT_YET_RECRUITING
• Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection — OTHER · PHASE1
• A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies — COMPLETED · PHASE3
• Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA — COMPLETED · PHASE3
• ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab — COMPLETED · PHASE3
• An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naïve Patients With Active SJIA With and Without Fever. — COMPLETED · PHASE3
• Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) — TERMINATED · PHASE3
• An Open-label, Multi-arm, Non-comparative Safety and Tolerability Study of Canakinumab (ACZ885) in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) — WITHDRAWN · PHASE3
• Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) — COMPLETED · PHASE1
• Ultrasonography in Juvenile Idiopathic Arthritis — COMPLETED
• Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) — COMPLETED · PHASE3
• Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) — COMPLETED · PHASE3
• Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) — COMPLETED · PHASE3

Refine this search